Background: Alzheimer's disease (AD) pathology shows characteristic 'plaques' rich in amyloid beta (Aβ) peptide deposits. Inflammatory process-related proteins such as pro-inflammatory cytokines have been detected in AD brain suggesting that an inflammatory immune reaction also plays a role in the pathogenesis of AD. Glial cells in culture respond to LPS and Aβ stimuli by upregulating the expression of cytokines TNF-α, IL-Iβ, and IL-6, and also the expression of proinflammatory genes INOS and COX-2. We have earlier reported that LPS /Aβ stimulation-induced ceramide and ROS generation leads to INOS expression and nitric oxide production in (a potent activator of AMP-activated protein kinase) in blocking the pro-oxidant /proinflammatory responses induced in primary glial cultures treated with LPS and Aβ peptide. Methods: To test and anti-inflammatory/anti-oxidant functions of AICAR, we tested its inhibitory potential in blocking the expression of pro-inflammatory cytokines and INOS, expression of COX-2, generation of ROS, and associated signaling following treatment of glial cells with LPS and Aβ peptide. We also investigated the neuroprotective effects of AICAR against the effects of cytokines and inflammatory mediators (released by the glia), in blocking neurite outgrowth inhibition, and in nerve growth factor-(NGF) induced neurite extension by PC-12 cells. Results: AICAR blocked LPS/Aβ-induced inflammatory processes by blocking the expression of proinflammatory cytokine, INOS, COX-2 and MnSOD genes, and by inhibition of ROS generation and depletion of glutathlone in astroglial cells. AICAR also inhibited down-stream signaling leading to the regulation of transcriptional factors such as NFκB and C/EBP which are critical for the expression of iNOS, COX-2, MnSOD and cytokines (TNF-α/IL-Iβ and IL-6). AICAR promoted NGF-induced neurite growth and reduced neurite outgrowth inhibition in PC-12 cells treated with astroglial conditioned medium. Conclusion: The observed anti-inflammatory/anti-oxidant and neuroprotective functions of AICAR suggest it as a viable candidate for use in treatment of Alzheimer's disease. © 2005 Ayasolla et al; licensee BioMed Central Ltd.
CITATION STYLE
Ayasolla, K. R., Singh, A. K., & Singh, I. (2005). 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) attenuates the expression of LPS- and Aβ peptide-induced inflammatory mediators in astroglia. Journal of Neuroinflammation, 2. https://doi.org/10.1186/1742-2094-2-21
Mendeley helps you to discover research relevant for your work.